6NOU
An scFv derived from ixekizumab
Experimental procedure
| Experimental method | SINGLE WAVELENGTH |
| Source type | SYNCHROTRON |
| Source details | ALS BEAMLINE 8.3.1 |
| Synchrotron site | ALS |
| Beamline | 8.3.1 |
| Temperature [K] | 100 |
| Detector technology | CCD |
| Collection date | 2011-01-14 |
| Detector | ADSC QUANTUM 315r |
| Wavelength(s) | 1.1159 |
| Spacegroup name | C 2 2 2 |
| Unit cell lengths | 94.445, 127.304, 43.023 |
| Unit cell angles | 90.00, 90.00, 90.00 |
Refinement procedure
| Resolution | 63.650 - 1.914 |
| R-factor | 0.182 |
| Rwork | 0.180 |
| R-free | 0.23400 |
| Structure solution method | MOLECULAR REPLACEMENT |
| RMSD bond length | 0.010 |
| RMSD bond angle | 1.070 |
| Data reduction software | MOSFLM |
| Data scaling software | SCALA (3.3.9) |
| Phasing software | PHASER |
| Refinement software | BUSTER (2.11.7) |
Data quality characteristics
| Overall | Inner shell | Outer shell | |
| Low resolution limit [Å] | 63.652 | 63.652 | 2.020 |
| High resolution limit [Å] | 1.914 | 6.050 | 1.914 |
| Rmerge | 0.019 | 0.480 | |
| Rmeas | 0.065 | 0.022 | 0.592 |
| Rpim | 0.026 | 0.010 | 0.240 |
| Total number of observations | 116086 | ||
| Number of reflections | 19243 | 715 | 2122 |
| <I/σ(I)> | 20.8 | 31.7 | 1.6 |
| Completeness [%] | 94.3 | 98.9 | 73.7 |
| Redundancy | 6 | 5.5 | 5.9 |
Crystallization Conditions
| crystal ID | method | pH | temperature | details |
| 1 | VAPOR DIFFUSION, SITTING DROP | 7 | 294 | 2800mM Sodium Acetate pH 7 |






